Steven W Pipe MD
Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology
Professor, Pediatrics & Communicable Diseases, University of Michigan Medical School
Join to View Full Profile
1500 E Medical Center DrD4207 MPBAnn Arbor, MI 48109
Phone+1 734-232-9335
Fax+1 734-615-0464
Dr. Pipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
MI State Medical License 1996 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Dose Confirmation Trial of AAV5-hFIXco-Padua Start of enrollment: 2018 Jul 24
- HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients Start of enrollment: 2018 Jun 27
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors Start of enrollment: 2019 Jan 30
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.Barbara A Konkle, Flora Peyvandi, Graham R Foster, Cedric Hermans, Vincenzo La Mura
Journal of Thrombosis and Haemostasis. 2025-03-14 - Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.Steven W Pipe, Toshko Lissitchkov, Pencho Georgiev, Sarah Mangles, Inga Hegemann
Blood Advances. 2025-03-11 - Operationalising a Haemophilia Gene Editing Lexicon for Practical Use.William McKeown, Cedric Hermans, Carmen Unzu, Mark A Kay, Flora Peyvandi
Haemophilia. 2025-03-01
Abstracts/Posters
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BSteven Pipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Positive Follow-up Results in Patients with Hemophilia B Given Gene Therapy (Hemgenix)March 19th, 2025
Etranacogene Dezaparvovec Shows Long-Term Bleed Protection, SafetyMarch 13th, 2025
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia BFebruary 9th, 2025- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
